ArticleAnnals of internal medicine2014
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Article in Annals of internal medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.BMC medical research methodology · 2018Pooled it
- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.PharmacoEconomics · 2016Pooled it
- A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care.PharmacoEconomics · 2025Review
- A scoping review on the community dividend resulting from testing and treating hepatitis C infection in people living in detention.Epidemiology and infection · 2024Article
- Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.The Kaohsiung journal of medical sciences · 2024Review
- Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs.American journal of preventive medicine · 2023Article
- Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.The International journal on drug policy · 2021Article
- New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019.Archives of public health = Archives belges de sante publique · 2021Article
- Article
- Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.BMJ global health · 2020Article
- Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses.Journal of managed care & specialty pharmacy · 2020Article
- Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis.PharmacoEconomics · 2020Article
- A Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease Management.Health care management science · 2019Article
- Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.Scientific reports · 2019Article
- Management of Hepatitis C in Delaware Prisons: : Approaching Microenvironmental Eradication.Delaware journal of public health · 2019Article
- Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States.Current hepatology reports · 2018Article
- HIV and hepatitis C virus infections in Quebec's provincial detention centres: comparing prevalence and related risky behaviours between 2003 and 2014-2015.Canadian journal of public health = Revue canadienne de sante publique · 2018Article
- Hepatitis C: Who should treat hepatitis C virus? The role of the primary care provider.Clinical liver disease · 2018Review
- Structural Sensitivity in HIV Modeling: A Case Study of Vaccination.Infectious Disease Modelling · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrevalence of chronic hepatitis C virus (HCV) infection is high among incarcerated persons in the United States. New, short-duration, high-efficacy therapies may expand treatment eligibility in this population.
objectiveTo assess the cost-effectiveness of sofosbuvir for HCV treatment in incarcerated populations.
designMarkov model. DATA SOURCES: Published literature and expert opinion. TARGET POPULATION: Treatment-naive men with chronic, genotype 1 HCV monoinfection. TIME HORIZON: Lifetime. PERSPECTIVE: Societal.
interventionNo treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir. For inmates with short remaining sentences (<1.5 years), only no treatment or sofosbuvir 3-drug therapy was feasible; for those with long sentences (≥1.5 years; mean, 10 years), all strategies were considered. After release, eligible persons could receive sofosbuvir 3-drug therapy. OUTCOME MEASURES: Discounted costs (in 2013 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: The strategies yielded 13.12, 13.57, 14.43, and 15.18 QALYs, respectively, for persons with long sentences. Sofosbuvir produced the largest absolute reductions in decompensated cirrhosis (16%) and hepatocellular carcinoma (9%), resulting in 2.1 additional QALYs at an added cost exceeding $54,000 compared with no treatment. For persons with short sentences, sofosbuvir cost $25,700 per QALY gained compared with no treatment; for those with long sentences, it dominated other treatments, costing $28,800 per QALY gained compared with no treatment. RESULTS OF SENSITIVITY ANALYSIS: High reinfection rates in prison attenuated cost-effectiveness for persons with long sentences. LIMITATIONS: Data on sofosbuvir's long-term effectiveness and price are limited. The analysis did not consider women, Hispanic persons, or patients co-infected with HIV or hepatitis B virus.
conclusionSofosbuvir-based treatment is cost-effective for incarcerated persons, but affordability is an important consideration. PRIMARY FUNDING SOURCE: National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.